Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcus Biosciences (RCUS) Equity Average (2018 - 2025)

Historic Equity Average for Arcus Biosciences (RCUS) over the last 8 years, with Q3 2025 value amounting to $492.5 million.

  • Arcus Biosciences' Equity Average fell 1791.67% to $492.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $492.5 million, marking a year-over-year decrease of 1791.67%. This contributed to the annual value of $473.5 million for FY2024, which is 1537.09% down from last year.
  • Latest data reveals that Arcus Biosciences reported Equity Average of $492.5 million as of Q3 2025, which was down 1791.67% from $540.0 million recorded in Q2 2025.
  • Arcus Biosciences' 5-year Equity Average high stood at $819.5 million for Q1 2022, and its period low was $491.0 million during Q4 2023.
  • Moreover, its 5-year median value for Equity Average was $584.5 million (2024), whereas its average is $612.8 million.
  • As far as peak fluctuations go, Arcus Biosciences' Equity Average skyrocketed by 28330.73% in 2021, and later plummeted by 2758.11% in 2023.
  • Over the past 5 years, Arcus Biosciences' Equity Average (Quarter) stood at $692.3 million in 2021, then decreased by 2.07% to $678.0 million in 2022, then dropped by 27.58% to $491.0 million in 2023, then increased by 6.92% to $525.0 million in 2024, then fell by 6.19% to $492.5 million in 2025.
  • Its Equity Average stands at $492.5 million for Q3 2025, versus $540.0 million for Q2 2025 and $508.0 million for Q1 2025.